Methylmercury pharmacokinetic model

Kedderis, G.L., and J.C. Lipscomb. 2001. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol. Ind. Health 17(5-10) 315-321. Kershaw T.G., T.W. Clarkson, and P.H. Dhahir. 1980. The relationship between blood levels and dose of methylmercury in man. Arch. Environ. Health 35(l) 28-36. 

Stern, A.H. 1997. Estimation of the interindividual variability in the one-compartment pharmacokinetic model for methylmercury Implications for the derivation of a reference dose. Regul. Toxicol. Pharmacol. 25(3) 277-288. 

Stern, A.H., M. Gochfeld, C. Weisel, and J. Burger. 2001. Mercury and methylmercury exposure in the New Jersey pregnant population. Arch Environ Health. 56(1) 4-10. Timchalk, C., R.J. Nolan, A.L. Mendrala, D.A. Dittenber, K.A. Brzak, and J.L. Mattsson. 2002. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci 66(1) 34-53. 

Young JF, Wosilait WD, Luecke RH. 2001. Analysis of methylmercury disposition in humans utilizing a PBPK model and animal pharmacokinetic data. J Toxicol Environ Health A 63 19-52. 

Table 2-6. Intercompartmental Mass Transport Parameters Used to Model Methylmercury and Mercuric Mercury Pharmacokinetics in Rats...

Two PBPK models have recently been published on the pharmacokinetics of methylmercury in rats (Farris et al. 1993 Gray 1995). Additional PBPK studies are needed to support species and dose extrapolations, and a better understanding of the underlying toxic and kinetic mechanisms is needed in support of human risk assessments. 

---